20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.
2 citations
,
January 1975 in “Archives of Dermatological Research” Certain enzymes react strongly with some hormones in rat skin during hair growth, mainly in sebaceous glands and hair sheaths.
115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” This article reviews how different 5alpha-reductase and 3alpha-HSD enzymes impact androgen levels and highlights their potential as drug targets for androgen-related diseases, but provides no new experimental findings.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
63 citations
,
November 1999 in “British journal of dermatology/British journal of dermatology, Supplement” This study observes the expression of mRNA for androgen receptor, 5α‐reductase, and 17β‐hydroxysteroid dehydrogenase in human dermal papilla cells.
45 citations
,
September 1998 in “Journal of Investigative Dermatology” This study found that sebaceous glands predominantly exhibit oxidative activity of the type 2 17β-hydroxysteroid dehydrogenase isozyme, which is not inhibited by 13-cis retinoic acid.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” This review explores the potential of selective 11β-HSD1 inhibitors to improve insulin sensitivity in type 2 diabetes, emphasizing the need for more clinical research and reports no new clinical results.
5 citations
,
July 2021 in “Endocrinology, diabetes & metabolism” This study found that glioblastoma cells express key enzymes involved in androgen synthesis, suggesting these enzymes might be potential targets for new therapeutic strategies.
February 2024 in “Cosmetics” In this study, researchers developed a novel platform for discovering potential hair loss inhibitors by investigating the testosterone/dihydrotestosterone biosynthetic pathway and its regulation through biochemical mechanisms involving 17β-HSD and 3β-HSD, combined with medicinal plant extracts.
7 citations
,
April 2019 in “The Journal of Steroid Biochemistry and Molecular Biology” This study found that 11α-hydroxyprogesterone is a potent inhibitor of 11βHSD2 in vitro and may serve as a precursor to unique C11α-hydroxy steroids in prostate cancer tissue.
354 citations
,
August 1991 in “Molecular Endocrinology” This study found that distinct isoenzymes of 3 beta-hydroxysteroid dehydrogenase are expressed in human adrenals and gonads compared to the placenta and skin.
119 citations
,
August 2010 in “Journal of Investigative Dermatology” This study reports that 11β-HSD1 activity in human skin increases with age and photoexposure, potentially contributing to skin aging and the effects of glucocorticoids.
98 citations
,
July 1983 in “Journal of Steroid Biochemistry” This study in the Arab population of Gaza described pseudohermaphroditism due to 17β-HSD deficiency, where individuals showed marked masculinization after puberty despite inadequate androgen proportions.
46 citations
,
December 1992 in “The Journal of Steroid Biochemistry and Molecular Biology” In this study, researchers observed that testicular 17β-hydroxysteroid dehydrogenase deficiency in an inbred Arab population in Israel leads to genital ambiguity at birth and progressive virilization after puberty.
34 citations
,
February 1999 in “Journal of Dermatological Science” This study found that minoxidil increased 17ß-hydroxysteroid dehydrogenase activity by nearly 40% in dermal papilla cells from balding scalps but not in nonbalding scalp cells or dermal fibroblasts.
26 citations
,
March 2006 in “Endocrine, metabolic & immune disorders. Drug targets” This article discusses the functions of the enzyme 17beta-HSD10, including its role in steroid metabolism and potential links to Alzheimer's disease, but reports no new experimental findings.
19 citations
,
March 2010 in “Bioorganic & Medicinal Chemistry Letters” This study evaluated curcumin analogues as potential inhibitors of 17β-HSD3 in rat and human models, but it does not report new clinical findings.
18 citations
,
December 2010 in “The Journal of Steroid Biochemistry and Molecular Biology” The authors concluded that increased expression of the HSD11B1 gene in adipose tissue correlates with obesity markers and predicts insulin resistance, but this association is independent of polycystic ovary syndrome when adiposity is controlled for.
11 citations
,
October 2002 in “The Journal of Clinical Endocrinology & Metabolism” This study found that prepubertal Hispanic girls with idiopathic premature adrenarche did not show differences in 5 alpha-reductase or 11 beta-hydroxysteroid dehydrogenase activities compared to controls.
3 citations
,
January 2017 in “Yonsei Medical Journal” This study found that inhibiting 11β-HSD1 can partially reverse the negative impact of glucocorticoids on dermal papilla cells in human scalps, suggesting potential for treating stress-related hair loss.
3 citations
,
May 1990 in “Journal of Steroid Biochemistry” This study found that diagnosing non-classical 3 beta-hydroxysteroid dehydrogenase deficiency solely based on elevated serum or urinary 5-ene-steroids may not be reliable.
1 citations
,
September 2017 in “Journal of Investigative Dermatology” The researchers reported that inhibiting 11β-HSD1 activity in human dermal papilla cells may reduce the negative effects of glucocorticoids on hair growth, suggesting potential treatment for stress-related hair loss.
November 2025 in “Russian Journal of Oncology” This review examines recent research on optimizing the structures of steroidal inhibitors for key steroidogenic enzymes used as cancer treatments, reporting on 209 new compounds with preclinical data that suggest structural modifications hold promise for developing new antineoplastic agents.
September 2025 in “JCEM Case Reports” In this case report, a 46-year-old woman initially diagnosed with 21-hydroxylase deficiency congenital adrenal hyperplasia was later identified as having 3β-HSD2 deficiency after further investigation, highlighting the need for awareness of rarer CAH forms to prevent delayed diagnosis and insufficient treatment.
May 2021 in “Journal of the Endocrine Society” This report presents a rare case of suspected 3β HSD deficiency in an adult female with symptoms like male pattern hair loss and low testosterone, suggesting a non-classical presentation.
This study explores the expression and function of 11β-HSD1 in human hair follicles and its potential regulation of glucocorticoid effects on dermal papilla cells, but reports no definitive findings on 11β-HSD1's role.
This invention reports piperazine derivatives as potent inhibitors of type 3 17β-hydroxysteroid dehydrogenase, suggesting potential therapeutic applications in treating prostate cancer, acne, and androgenic alopecia.
January 1983 in “Elsevier eBooks” Masculinization in affected individuals occurs gradually after puberty due to hormone changes.
69 citations
,
August 1988 in “Journal of Investigative Dermatology” 46 citations
,
August 2006 in “PubMed” In this study, researchers identified and examined males with 17 beta-HSD3 deficiency in a highly inbred Arab population, noting genetic findings and the progression of male characteristics despite being raised as females initially.